RemeGen CoREGMF -6.23%41 PB Ratio is 13.26 as of Jul. 11, 2026, which is 141% above its 10-year median of 5.51. GuruFocus rates REGMF with a GF Score™ of 41/100 and a GF Value™ of $27.02 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,227 Biotechnology companies, RemeGen Co ranks worse than 87.94% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-11), RemeGen Co's share price is $12.05. RemeGen Co's Book Value per Share for the quarter that ended in Dec. 2025 was $0.91. Hence, RemeGen Co's PB Ratio of today is 13.26.
The historical rank and industry rank for RemeGen Co's PB Ratio or its related term are showing as below:
REGMF'
s PB Ratio Range Over the Past 10 Years
Min: 2.03 Med: 5.51 Max: 27.78
Current: 11.89
During the past 8 years, RemeGen Co's highest PB Ratio was 27.78. The lowest was 2.03. And the median was 5.51.
REGMF's PB Ratio is ranked worse than 87.94% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs REGMF: 11.89
During the past 12 months, RemeGen Co's average Book Value Per Share Growth Rate was 81.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -10.30% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of RemeGen Co was -7.40% per year. The lowest was -23.20% per year. And the median was -11.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
RemeGen Co PB Ratio Related Terms
RemeGen Co PB Ratio Historical Data
* Premium members only.
The historical data trend for RemeGen Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, RemeGen Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where RemeGen Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
RemeGen Co's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
RemeGen Co (REGMF) has a PB Ratio of 13.26 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RemeGen Co and its competitors. This is 141% above median its historical median of 5.51. Over the past decade, RemeGen Co's PB Ratio has ranged from 2.03 to 27.78. According to the industry distribution chart, RemeGen Co ranks #1079 out of 1227 companies in the Biotechnology industry, placing it in the top 87.9%.
Is RemeGen Co's PB Ratio too high?
RemeGen Co's current PB Ratio of 13.26 is 141% above median its 10-year median of 5.51. Over the past 10 years, this metric has ranged from a low of 2.03 to a high of 27.78. The Biotechnology industry median PB Ratio is 2.95. RemeGen Co's value of 13.26 is 349.5% above this industry median. Based on the distribution chart, RemeGen Co ranks #1079 out of 1227 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RemeGen Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #1079 out of 1227 companies for PB Ratio. This places RemeGen Co in the lower half of its industry. The industry median PB Ratio is 2.95. RemeGen Co's value of 13.26 is 349.5% above this benchmark. Historically, RemeGen Co's own PB Ratio has ranged from 2.03 to 27.78 over the past decade. While the company's 10-year median is 5.51 vs. the industry median of 2.95, RemeGen Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current PB Ratio of 13.26 is 349.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current PB Ratio is 13.26, which is 141% above median its own 10-year median of 5.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (REGMF) is currently considered Possible Value Trap. The stock's GF Value™ is $27.02, compared to a current price of $12.05 — trading 55.4% below its estimated fair value. The current PB Ratio is 13.26, which is 141% above median its 10-year median of 5.51 and 349.5% above the Biotechnology industry median of 2.95. RemeGen Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For RemeGen Co (REGMF), the current PB Ratio is 13.26 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (REGMF) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of $12.05 is trading 55.4% below its estimated GF Value™ of $27.02.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for REGMF:
PB Ratio: 13.26 (141% above median its 10-year median of 5.51)
GF Value™: $27.02 vs. price of $12.05 (55.4% below fair value)
Industry Position: 349.5% above the Biotechnology median (#1079 of 1227)
No single metric tells the full story. See the REGMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
41GF Score
Get the complete analysis for REGMF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REGMF has been successfully added to your 
